chronic obstructive pulmonary disease

‘Encouraging’ COPD drug pipeline could ease symptoms, address root causesAlbert A. Rizzo, MD, senior medical advisor for the American Lung Association, says the increasing number of drugs in the pipeline could improve airflow address the underlying disease process.
COPD patient education needs, challenges: What health execs should knowEducation is a significant element of comprehensive care for COPD patients. In this Q&A, one expert shares her recommendations.
How population, community health goals overlapA new study found that distinguishing between population health and community health strategies can help health organizations define clear goals and earmark the right resources to accomplish them.
What providers need to do to improve chronic care
What providers need to do to improve chronic careA West survey finds that an overwhelming number of chronic care patients say they need help managing their disease.
Study finds hike in pneumonia for COPD patients receiving corticosteroidsComorbid CVD is an independent risk factor for CAP in patients with COPD. And inhaled steroids may increase CAP risk.
A Triple Hitter in One Blast: COPD Lessons from TRILOGYPatients with severe COPD are likely to suffer frequent disease exacerbations and a reduced quality of life.
QD Fluticasone-Vilanterol combo reduces COPD exacerbationsIn patients with COPD who have a history of exacerbations, a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with fewer exacerbations than usual care without a greater risk of serious adverse events
COPD and pharmacotherapy for smoking cessation at the VA: StudyUse of tobacco-cessation therapy was low. The study found several negative factors — and two positive predictors.
Umeclidinium triple therapy for patients with COPD: Two studiesBoth studies demonstrated statistical improvements in trough FEV1 at day 85.
FDA approves new COPD treatmentsFDA approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) and the stand-alone monotherapy Seebri Neohaler (glycopyrrolate) – which is one component of Utibron Neohaler -- for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.